The prevention of H. influenzae type b, (Hib), pneumococcal and meningococcal infections would be a major advance. These organisms are the major bacterial causes of meningitis, blood stream infection, pneumonia and middle ear infections in children and adults. The work accomplished during the first two years of this grant has demonstrated the feasibility of preparing a human hyperimmune globulin (termed Bacterial Polysaccharide Immune Gobulin okr BPIG) high concentrations of antibody against these organisms. The pharmacologic studies indicate that """"""""protective"""""""" antibody levels to Hib are maintained for at least 4 months after a single im dose. Passive BPIG prophylaxis therefore has a high probability of success. Even if capsular polysaaccharide vaccines of improved immunogenicity can be developed, passive prophylaxis used instead of or in conjuction with active immunization is likely to be useful in selected high-risk children. We propose to continue our investigations by preparing sufficient BPIG for additional pharmaclogic studies and large-scale efficacy trials in the prevention of bacteremia meningitis, pneumonia, and recurrent otitis media. In addition, we will optimize methods of production by immunizing donors with new maximally immunogenic vaccines and evaluate genetic markers which identify donors with high and persistent IgG-class antibody responses. We will develop guidelines for standardizing the specific antibody concentrations required in the final globulin. An intravenous formulation of BPIG will be evaluated in humans. Experimental studies will be done to evaluate the safety and efficacy of hyperimmune globulin in the treatment of establishd Hib infections. Finally, we will exploit the availability of large volumes of human hyperimmune plasma by purifying IgG, IgM and IgA immunoglobulins and examining their actions and interactions against Hib in bactericidal and opsonophagocytic assays and in animal models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI018125-06
Application #
3127707
Study Section
Bacteriology and Mycology Subcommittee 1 (BM)
Project Start
1981-08-01
Project End
1989-07-31
Budget Start
1986-08-01
Budget End
1987-07-31
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Perez-Perez, Guillermo I; Sack, R Bradley; Reid, Raymond et al. (2003) Transient and persistent Helicobacter pylori colonization in Native American children. J Clin Microbiol 41:2401-7
Englund, J A; Glezen, W P; Thompson, C et al. (1997) Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Pediatr Infect Dis J 16:1122-30
Nahm, M H; Siber, G R; Olander, J V (1996) A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. J Infect Dis 173:113-8
Saladino, R A; Stack, A M; Thompson, C et al. (1996) High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis. Crit Care Med 24:1203-7
Samore, M H; Siber, G R (1996) Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Vaccine 14:290-7
Nelson, D; Kuppermann, N; Fleisher, G R et al. (1995) Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats. Crit Care Med 23:92-8
Englund, J A; Glezen, W P; Turner, C et al. (1995) Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis 171:99-105
Saladino, R; Garcia, C; Thompson, C et al. (1994) Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis. Circ Shock 42:104-10
Kuppermann, N; Nelson, D S; Saladino, R A et al. (1994) Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats. J Infect Dis 170:630-5
Garcia, C; Saladino, R; Thompson, C et al. (1994) Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits. Crit Care Med 22:1211-8

Showing the most recent 10 out of 42 publications